These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

676 related articles for article (PubMed ID: 34263665)

  • 1. Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study.
    Modi S
    Future Oncol; 2021 Sep; 17(26):3415-3423. PubMed ID: 34263665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer: a plain language summary of the DESTINY-Gastric01 study.
    Shitara K
    Future Oncol; 2024 Jan; 20(2):59-70. PubMed ID: 37916503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01).
    Saura C; Modi S; Krop I; Park YH; Kim SB; Tamura K; Iwata H; Tsurutani J; Sohn J; Mathias E; Liu Y; Cathcart J; Singh J; Yamashita T
    Ann Oncol; 2024 Mar; 35(3):302-307. PubMed ID: 38092229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exposure-Response Relationships in Patients With HER2-Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan.
    Yin O; Iwata H; Lin CC; Tamura K; Watanabe J; Wada R; Kastrissios H; AbuTarif M; Garimella T; Lee C; Zhang L; Shahidi J; LaCreta F
    Clin Pharmacol Ther; 2021 Oct; 110(4):986-996. PubMed ID: 33999422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab deruxtecan for HER2+ advanced breast cancer.
    Lee J; Park YH
    Future Oncol; 2022 Jan; 18(1):7-19. PubMed ID: 34823373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.
    Petit T; Hajjaji N; Antoine EC; Benderra MA; Gozy M; Foa C; Mouysset JL; Grenier J; Mousseau M; Mailliez A; Saghatchian M; Lachaier E; Desmoulins I; Hennequin A; Maes P; Loirat D; Ricci F; Diéras V; Berton D; Tiong FL; Teixeira L; Dohollou N; Lévy C; Bachelot T; Pierga JY
    Cancer Med; 2024 May; 13(9):e7168. PubMed ID: 38733172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer.
    Rugo HS; Bianchini G; Cortes J; Henning JW; Untch M
    ESMO Open; 2022 Aug; 7(4):100553. PubMed ID: 35964548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
    Modi S; Saura C; Yamashita T; Park YH; Kim SB; Tamura K; Andre F; Iwata H; Ito Y; Tsurutani J; Sohn J; Denduluri N; Perrin C; Aogi K; Tokunaga E; Im SA; Lee KS; Hurvitz SA; Cortes J; Lee C; Chen S; Zhang L; Shahidi J; Yver A; Krop I;
    N Engl J Med; 2020 Feb; 382(7):610-621. PubMed ID: 31825192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management of Selected Adverse Events Associated with Trastuzumab Deruxtecan.
    Bardia A; Harnden K; Mauro L; Pennisi A; Armitage M; Soliman H
    Oncologist; 2022 Aug; 27(8):637-645. PubMed ID: 35642907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.
    Hurvitz SA; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Egorov A; Liu Y; Cathcart J; Bako E; Tecson K; Verma S; Cortés J
    ESMO Open; 2024 May; 9(5):102924. PubMed ID: 38796287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
    André F; Hee Park Y; Kim SB; Takano T; Im SA; Borges G; Lima JP; Aksoy S; Gavila Gregori J; De Laurentiis M; Bianchini G; Roylance R; Miyoshi Y; Armstrong A; Sinha R; Ruiz Borrego M; Lim E; Ettl J; Yerushalmi R; Zagouri F; Duhoux FP; Fehm T; Gambhire D; Cathcart J; Wu C; Chu C; Egorov A; Krop I
    Lancet; 2023 May; 401(10390):1773-1785. PubMed ID: 37086745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study.
    Curigliano G; Dunton K; Rosenlund M; Janek M; Cathcart J; Liu Y; Fasching PA; Iwata H
    Ann Oncol; 2023 Jul; 34(7):569-577. PubMed ID: 37179020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer: a plain language summary of the DESTINY-Lung01 study.
    Smit EF
    Future Oncol; 2024 Jul; ():1-11. PubMed ID: 39012221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer.
    Narayan P; Osgood CL; Singh H; Chiu HJ; Ricks TK; Chiu Yuen Chow E; Qiu J; Song P; Yu J; Namuswe F; Guiterrez-Lugo M; Hou S; Pierce WF; Goldberg KB; Tang S; Amiri-Kordestani L; Theoret MR; Pazdur R; Beaver JA
    Clin Cancer Res; 2021 Aug; 27(16):4478-4485. PubMed ID: 33753456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.
    Indini A; Rijavec E; Grossi F
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer.
    Bartsch R
    Expert Opin Investig Drugs; 2020 Sep; 29(9):901-910. PubMed ID: 32701032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland.
    Paulissen JHJ; Seddik AH; Dunton KJ; Livings CJ; van Hulst M; Postma MJ; de Jong LA; Freriks RD
    Eur J Health Econ; 2024 Jun; 25(4):689-699. PubMed ID: 37486557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer.
    Bardia A; Jhaveri K; Kalinsky K; Pernas S; Tsurutani J; Xu B; Hamilton E; Im SA; Nowecki Z; Sohn J; Laurentiis M; Jañez NM; Adamo B; Lee KS; Jung KH; Rubovszky G; Tseng LM; Lu YS; Yuan Y; Maxwell MJ; Haddad V; Khan SS; Rugo HS; Pistilli B
    Future Oncol; 2024 Mar; 20(8):423-436. PubMed ID: 37387213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
    Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
    Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis.
    Jerusalem G; Park YH; Yamashita T; Hurvitz SA; Modi S; Andre F; Krop IE; Gonzàlez Farré X; You B; Saura C; Kim SB; Osborne CR; Murthy RK; Gianni L; Takano T; Liu Y; Cathcart J; Lee C; Perrin C
    Cancer Discov; 2022 Dec; 12(12):2754-2762. PubMed ID: 36255231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.